Annotation Detail for SLC35D2
Basic Information
Top
| Pathway ID | Pathway Name |
|---|
| Transmembrane transport of small molecules |
| Pathway ID | Pathway Name |
|---|
| 500363 | Transport of nucleotide sugars |
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| C016403 |
2,4-dinitrotoluene |
2,4-dinitrotoluene affects the expression of SLC35D2 mRNA | affects expression | 21346803
|
| C023514 |
2,6-dinitrotoluene |
2,6-dinitrotoluene affects the expression of SLC35D2 mRNA | affects expression | 21346803
|
| D016604 |
Aflatoxin B1 |
Aflatoxin B1 affects the expression of SLC35D2 protein | affects expression | 20106945
|
| D016572 |
Cyclosporine |
Cyclosporine results in decreased expression of SLC35D2 mRNA | decreases expression | 20106945
|
| C006253 |
pirinixic acid |
[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of SLC35D2 mRNA | affects binding|decreases expression|increases activity | 19710929
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D055371 |
Acute Lung Injury |
|
pirinixic acid |
3.52 | 18653653 |
| MESH:D018248 |
Adenoma, Liver Cell |
|
pirinixic acid |
4.02 | 16434500 |
| MESH:D001778 |
Blood Coagulation Disorders |
|
pirinixic acid |
3.52 | 19483382 |
| MESH:D006528 |
Carcinoma, Hepatocellular |
|
2,4-dinitrotoluene |
4.83 | 16705839 |
| MESH:D006528 |
Carcinoma, Hepatocellular |
|
2,6-dinitrotoluene |
4.83 | 16705839 |
| MESH:D006528 |
Carcinoma, Hepatocellular |
|
Aflatoxin B1 |
4.83 | 12907637 12619106 21507988 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
2,6-dinitrotoluene |
7.36 | 6135515 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cyclosporine |
7.36 | 12371664 |
| MESH:D002779 |
Cholestasis |
|
Cyclosporine |
8.63 | 19486331 |
| MESH:D002779 |
Cholestasis |
|
pirinixic acid |
8.63 | 19176532 |
| MESH:D003490 |
Cyanosis |
|
2,4-dinitrotoluene |
12.56 | 18551238 |
| MESH:D003490 |
Cyanosis |
|
2,6-dinitrotoluene |
12.56 | 18551238 |
| MESH:D003876 |
Dermatitis, Atopic |
|
pirinixic acid |
2.56 | 18249437 |
| MESH:D056486 |
Drug-Induced Liver Injury |
|
2,4-dinitrotoluene |
4.13 | 18551238 21346803 |
| MESH:D056486 |
Drug-Induced Liver Injury |
|
2,6-dinitrotoluene |
4.13 | 21346803 18551238 |
| MESH:D004487 |
Edema |
|
pirinixic acid |
2.85 | 12083418 |
| MESH:D005234 |
Fatty Liver |
|
Cyclosporine |
8.82 | 19224547 |
| MESH:D005234 |
Fatty Liver |
|
pirinixic acid |
8.82 | 19236843 20131406 |
| MESH:D005355 |
Fibrosis |
|
Cyclosporine |
3.62 | 12639820 12168785 |
| MESH:D005885 |
Gingival Hyperplasia |
|
Cyclosporine |
4.76 | 8708960 |
| MESH:D006333 |
Heart Failure |
|
pirinixic acid |
2.73 | 20558911 |
| MESH:D006457 |
Hemoglobinuria, Paroxysmal |
|
Cyclosporine |
4.96 | 15720958 |
| MESH:D006529 |
Hepatomegaly |
|
pirinixic acid |
3.48 | 16221962 19176532 19772884 18467677 |
| MESH:D006943 |
Hyperglycemia |
|
pirinixic acid |
3.53 | 20558911 |
| MESH:D006973 |
Hypertension |
|
Cyclosporine |
2.20 | 10903974 |
| MESH:D007333 |
Insulin Resistance |
|
pirinixic acid |
2.85 | 16306350 |
| MESH:D007638 |
Keratoconjunctivitis Sicca |
|
Cyclosporine |
5.05 | 15604871 |
| MESH:D007674 |
Kidney Diseases |
|
Cyclosporine |
2.52 | 8314463 10903974 18776723 |
| MESH:D007680 |
Kidney Neoplasms |
|
2,4-dinitrotoluene |
14.20 | 16705839 |
| MESH:D007680 |
Kidney Neoplasms |
|
2,6-dinitrotoluene |
14.20 | 16705839 |
| MESH:D007680 |
Kidney Neoplasms |
|
Cyclosporine |
14.20 | 12371664 |
| MESH:D008106 |
Liver Cirrhosis, Experimental |
|
pirinixic acid |
1.35 | 15474484 |
| MESH:D008113 |
Liver Neoplasms |
|
2,6-dinitrotoluene |
8.06 | 7678174 |
| MESH:D008113 |
Liver Neoplasms |
|
Aflatoxin B1 |
8.06 | 18177683 2125692 9163691 15890375 |
| MESH:D008113 |
Liver Neoplasms |
|
pirinixic acid |
8.06 | 15890375 20007298 16377806 |
| MESH:D008114 |
Liver Neoplasms, Experimental |
|
2,6-dinitrotoluene |
6.65 | 6135515 2876784 2876786 |
| MESH:D008114 |
Liver Neoplasms, Experimental |
|
Aflatoxin B1 |
6.65 | 8603461 |
| MESH:D008175 |
Lung Neoplasms |
|
Aflatoxin B1 |
1.88 | 14755239 |
| MESH:D008664 |
Metal Metabolism, Inborn Errors |
|
Cyclosporine |
5.40 | 16801185 |
| MESH:D009135 |
Muscular Diseases |
|
pirinixic acid |
3.99 | 16239165 |
| MESH:D009203 |
Myocardial Infarction |
|
pirinixic acid |
2.26 | 19151258 |
| MESH:D015428 |
Myocardial Reperfusion Injury |
|
pirinixic acid |
3.22 | 16411023 |
| MESH:D009336 |
Necrosis |
|
2,4-dinitrotoluene |
12.21 | 18551238 |
| MESH:D009336 |
Necrosis |
|
2,6-dinitrotoluene |
12.21 | 7678174 18551238 |
| MESH:D009369 |
Neoplasms |
|
pirinixic acid |
2.09 | 17405874 |
| MESH:D009402 |
Nephrosis, Lipoid |
|
Cyclosporine |
5.05 | 17954296 |
| MESH:D009404 |
Nephrotic Syndrome |
|
Cyclosporine |
3.61 | 19348381 18481113 |
| MESH:D009765 |
Obesity |
|
pirinixic acid |
1.88 | 20558911 |
| MESH:D009784 |
Occupational Diseases |
|
2,4-dinitrotoluene |
10.06 | 12819281 16049721 |
| MESH:D009784 |
Occupational Diseases |
|
2,6-dinitrotoluene |
10.06 | 16049721 |
| MESH:D011230 |
Precancerous Conditions |
|
Cyclosporine |
3.55 | 12371664 |
| MESH:D011565 |
Psoriasis |
|
Cyclosporine |
2.32 | 16882103 |
| MESH:D015427 |
Reperfusion Injury |
|
pirinixic acid |
2.53 | 19058328 |
| MESH:D012640 |
Seizures |
|
2,4-dinitrotoluene |
6.65 | 18551238 |
| MESH:D012640 |
Seizures |
|
2,6-dinitrotoluene |
6.65 | 18551238 |
| MESH:D001749 |
Urinary Bladder Neoplasms |
|
2,4-dinitrotoluene |
5.39 | 16049721 |
| MESH:D001749 |
Urinary Bladder Neoplasms |
|
2,6-dinitrotoluene |
5.39 | 16049721 |
| MESH:D014571 |
Urologic Neoplasms |
|
2,4-dinitrotoluene |
13.86 | 10091137 |
| MESH:D014571 |
Urologic Neoplasms |
|
2,6-dinitrotoluene |
13.86 | 10091137 |
| MESH:D014605 |
Uveitis |
|
Cyclosporine |
4.59 | 1336536 |
| MESH:D014985 |
Xerophthalmia |
|
Cyclosporine |
5.05 | 17120751 |
| Pathway ID |
Pathway Name |
|---|
| REACT:15518 |
Transmembrane transport of small molecules |
Related Diseases/Disorders